ClinicalTrials.gg
CompletedNCT00746330Updated Jun 7, 2011Results posted

Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma

A Phase 2 interventional study of Mometasone furoate/formoterol fumarate (MFF) and Formoterol fumarate 12 μg pMDI (F12M) in Asthma, sponsored by Novartis. Completed at 9 sites in 3 countries. Open to participants aged 5 Years to 11 Years. Per ClinicalTrials.gov, last updated 2011-06-07.

Sponsored by Novartis · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
5 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 31 studies testing Mometasone Furoate in Asthma — none open to participants now, none under way, none of them phase 3. Mometasone Furoate · Asthma.

Enrollment
23rd of 31
32 · median 92
Started
2008
with 2 others
Phase 2
6 of 31
none open now
Registered
16th of 31
by date

Among the 31 studies testing Mometasone Furoate in Asthma, this one is the 23rd largest by enrollment, is one of 3 that started in 2008, is one of 6 in phase 2, and was the 16th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 31 studies testing Mometasone Furoate in Asthma is open now. The open studies under Asthma, anywhere →

About Mometasone Furoate

Mometasone Furoate: first FDA approval 1987 (ELOCON), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 5 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 31 studies testing Mometasone Furoate in Asthma as a file.
02

Study summary

This study is being conducted to compare the pharmacodynamics (bronchodilation, onset and duration of action), of a single dose of formoterol fumarate in combination with mometasone furoate to placebo in children of 5-11 years with persistent asthma. The study will also assess the bronchodilatory effect of a single dose of formoterol fumarate alone and in combination with mometasone furoate delivered via a pressurized metered dose inhaler (pMDI) to the bronchodilatory effect of formoterol fumarate delivered via a dry powder inhaler (DPI). Furthermore, pharmacokinetic assessments of plasma and urine will also be conducted throughout the study to assess systemic exposure following administration of the study medication.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • Children
  • Persistent asthma
04

Who can participate

Ages eligible
5 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 5 to 11 years of age of either sex and of any race
  • A diagnosis (according to the Global Initiative for Asthma [GINA] guidelines) of persistent asthma for a period of at least 6 months prior to screening and must have been on a stable asthma regimen (daily dose unchanged) for at least 4 weeks prior to screening
  • β2-agonist reversibility, defined as an increase in absolute of ≥12% within 30 minutes after administration of 200μg of salbutamol without the use of a spacer or its equivalent in accordance with ATS/ERS standards
  • A child must have an FEV1 of ≥ 60% and ≤ 90% of Polgar predicted when all restricted medications have been withheld for the appropriate intervals

Exclusion criteria

Exclusion Criteria:

  • Use of other drugs at the time of enrolment, or within 30 days or 5 half-lives of enrolment, whichever is longer.
  • History of of any organ system within past 5 years.
  • Pre-dose change (increase or decrease) in absolute of 15% at Visit 2, compared with value at screening.
  • Hospitalized or had an emergency room treatment for an acute asthma exacerbation in the 1 month prior to Visit 1, or who had a clinical deterioration of asthma between Visits 1 and 2 that resulted in emergency treatment, hospitalization, or treatment with excluded asthma medication.
  • Significant medication condition or situation.
  • > 440 msec (boys) or > 450 msec (girls) on (ECG) assessment at screening.
  • Upper or lower respiratory tract infection within 4 weeks prior to screening.
  • Chronic conditions affecting the respiratory tract or chronic lung diseases.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    F12M - PL - F12D - MFF

    Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 2: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 3: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 4: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.

    Drug: Mometasone furoate/formoterol fumarate (MFF) · Drug: Formoterol fumarate 12 μg pMDI (F12M) · Drug: Formoterol fumarate 12 μg DPI (F12D) · Drug: Placebo to F12D · Drug: Placebo to F12M/MFF

  • Experimental
    F12D - F12M - MFF - PL

    Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 2: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 3: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 4: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.

    Drug: Mometasone furoate/formoterol fumarate (MFF) · Drug: Formoterol fumarate 12 μg pMDI (F12M) · Drug: Formoterol fumarate 12 μg DPI (F12D) · Drug: Placebo to F12D · Drug: Placebo to F12M/MFF

  • Experimental
    MFF - F12D - PL - F12M

    Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 2: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 3: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 4: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.

    Drug: Mometasone furoate/formoterol fumarate (MFF) · Drug: Formoterol fumarate 12 μg pMDI (F12M) · Drug: Formoterol fumarate 12 μg DPI (F12D) · Drug: Placebo to F12D · Drug: Placebo to F12M/MFF

  • Experimental
    PL - MFF - F12M - F12D

    Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 2: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 3: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 4: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.

    Drug: Mometasone furoate/formoterol fumarate (MFF) · Drug: Formoterol fumarate 12 μg pMDI (F12M) · Drug: Formoterol fumarate 12 μg DPI (F12D) · Drug: Placebo to F12D · Drug: Placebo to F12M/MFF

Interventions

  • DrugMometasone furoate/formoterol fumarate (MFF)

    Drug pages: Mometasone Furoate · Formoterol

    Formoterol fumarate dihydrate / mometasone furoate combination product 10 μg / 100 μg delivered via Pressurized Metered Dose Inhaler (pMDI). One dose consisted of 2 puffs x 5 μg / 50 μg.

  • Formoterol fumarate dihydrate 12 μg delivered via Pressurized Metered Dose Inhaler (pMDI) (1 dose = 2 puffs x 6 μg).

  • Formoterol fumarate dihydrate 12 μg delivered via Dry Powder Inhaler (DPI).

  • DrugPlacebo to F12D

    Placebo to formoterol fumarate DPI delivered via DPI

  • DrugPlacebo to F12M/MFF

    Placebo to formoterol fumarate pMDI and formoterol fumarate / mometasone furoate delivered via pMDI

06

What researchers measure

Primary outcomes

  1. The Standardized Forced Expiratory Volume in 1 Second (FEV1) Using Area Under the Curve (AUC) From 0 to 12 Hours (0-12h) Post-dose by Treatment

    For FEV1 AUC(0-12h) the trapezoidal rule was applied using planned time measurements to calculate the AUC up to and including the last measurement recorded before intake of rescue medication. The AUC was standardized by dividing by the length of time for which measurements of FEV1 were included in the calculation of the AUC thus adjusting for subjects who were unable to complete the measurements during the 12-hour observation period and without inhaling rescue medication. The unit of the AUC was in L, being a weighted average of the acceptable FEV1 measurements recorded over 12 hours post dose

    Time frame: From 0 to 12 Hours (0-12h) post-dose, after each treatment administered (approximately 1 treatment a week for 4 weeks of treatment).

Secondary outcomes

  1. Serial FEV1 Measurement (i.e. at 5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose) Following Inhalation of a Single Dose of Study Medication to Evaluate the Onset and Duration of the Bronchodilatory Effect

    All efficacy evaluations were based on spirometry assessments of lung function. FEV1 is the maximum amount of air expired in one second. At Visits 2, 3, 4 and 5, spirometry assessments were performed in the clinic at predose and again at 5 and 30 minutes and 1, 2, 4, 8 and 12 hours post-dose within ± 5 minutes of the scheduled time for the time points up to and including 60 minutes post-dose and then within ± 10 minutes for all subsequent time points. Spirometry equipment and performance of spirometric testing were in accordance with the (ATS / ERS) standards.

    Time frame: 5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose

  2. Serial Forced Vital Capacity (FVC) Measurement (i.e. at 5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose) Following Inhalation of a Single Dose of Study Medication to Evaluate the Onset and Duration of the Bronchodilatory Effect

    All efficacy evaluations were based on spirometry assessments of lung function. FVC is the volume (liters) of air that can forcibly be blown out after full inspiration. At Visits 2, 3, 4 and 5, spirometry assessments were performed in the clinic at predose and again at 5 and 30 minutes and 1, 2, 4, 8 and 12 hours post-dose within ± 5 minutes of the scheduled time for the time points up to and including 60 minutes post-dose and then within ± 10 minutes for all subsequent time points. Spirometry equipment and performance of spirometric testing were in accordance with the ATS / ERS standards.

    Time frame: 5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose

  3. Serial Peak Expiratory Flow Rate (PEF) Measurement (i.e. at 5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose) Following Inhalation of a Single Dose of Study Medication to Evaluate the Onset and Duration of the Bronchodilatory Effect

    All efficacy evaluations were based on spirometry assessments of lung function. PEF is the greatest airflow rate achieved during forced exhalation with lungs fully inflated. At Visits 2, 3, 4 and 5, spirometry assessments were performed in the clinic at predose and again at 5 and 30 minutes and 1, 2, 4, 8 and 12 hours post-dose within ± 5 minutes of the scheduled time for the time points up to and including 60 minutes post-dose and then within ± 10 minutes for all subsequent time points. Spirometry equipment and performance of spirometric testing were in accordance with the ATS/ERS standards

    Time frame: 5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose

  4. Plasma Formoterol Concentrations (Pmol/L) Following a Single Dose of Formoterol Fumarate Alone and in Combination With Mometasone Furoate Via the pMDI and Formoterol Fumarate Via the Dry Powder Inhaler (DPI)

    Unchanged racemic formoterol in plasma was assayed by LC-MS/MS. The lower limit of quantification (LLOQ) for plasma was 1.45 pmol/L. No non-compartmental PK analysis was performed.

    Time frame: 5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose

  5. Urinary Excretion of Formoterol Following a Single Dose of Formoterol Fumarate Alone and in Combination With Mometasone Furoate Via the pMDI and Formoterol Fumarate Via the Dry Powder Inhaler (DPI)

    Unchanged racemic formoterol in urine was assayed by LC-MS/MS. The lower limit of quantification (LLOQ) for urine was 0.0174 nmol/L expressed as free base. The amounts of unchanged formoterol excreted in urine from 0 to 3 hours (Ae0-3) and from 0 to 12 hours post-dose (Ae0-12) were calculated from the formoterol concentrations in urine and the urine volumes using non-compartmental methods.

    Time frame: 0 to 3 hrs and 0-12 hrs

07

Results

Posted Apr 14, 2011

Participant flow

Period 1
Participant flow — Period 1
MilestoneF12M, PL, F12D, MFFF12D, F12M, MFF, PLMFF, F12D, PL, F12MPL, MFF, F12M, F12D
Started7997
Completed7987
Not completed0010
Withdrew: Abnormal test procedure result0010
Period 2
Participant flow — Period 2
MilestoneF12M, PL, F12D, MFFF12D, F12M, MFF, PLMFF, F12D, PL, F12MPL, MFF, F12M, F12D
Started7987
Completed7987
Not completed0000
Period 3
Participant flow — Period 3
MilestoneF12M, PL, F12D, MFFF12D, F12M, MFF, PLMFF, F12D, PL, F12MPL, MFF, F12M, F12D
Started7987
Completed7987
Not completed0000
Period 4
Participant flow — Period 4
MilestoneF12M, PL, F12D, MFFF12D, F12M, MFF, PLMFF, F12D, PL, F12MPL, MFF, F12M, F12D
Started7987
Completed7987
Not completed0000

Outcome measures

PrimaryThe Standardized Forced Expiratory Volume in 1 Second (FEV1) Using Area Under the Curve (AUC) From 0 to 12 Hours (0-12h) Post-dose by Treatment

For FEV1 AUC(0-12h) the trapezoidal rule was applied using planned time measurements to calculate the AUC up to and including the last measurement recorded before intake of rescue medication. The AUC was standardized by dividing by the length of time for which measurements of FEV1 were included in the calculation of the AUC thus adjusting for subjects who were unable to complete the measurements during the 12-hour observation period and without inhaling rescue medication. The unit of the AUC was in L, being a weighted average of the acceptable FEV1 measurements recorded over 12 hours post dose

Time frame:
From 0 to 12 Hours (0-12h) post-dose, after each treatment administered (approximately 1 treatment a week for 4 weeks of treatment).
Reported as:
Least squares mean · liters
The Standardized Forced Expiratory Volume in 1 Second (FEV1) Using Area Under the Curve (AUC) From 0 to 12 Hours (0-12h) Post-dose by Treatment
litersMFF10F12MF12DPlacebo
The Standardized Forced Expiratory Volume in 1 Second (FEV1) Using Area Under the Curve (AUC) From 0 to 12 Hours (0-12h) Post-dose by Treatment1.77 ± .0421.77 ± .0421.80 ± .0421.71 ± .042
SecondarySerial FEV1 Measurement (i.e. at 5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose) Following Inhalation of a Single Dose of Study Medication to Evaluate the Onset and Duration of the Bronchodilatory Effect

All efficacy evaluations were based on spirometry assessments of lung function. FEV1 is the maximum amount of air expired in one second. At Visits 2, 3, 4 and 5, spirometry assessments were performed in the clinic at predose and again at 5 and 30 minutes and 1, 2, 4, 8 and 12 hours post-dose within ± 5 minutes of the scheduled time for the time points up to and including 60 minutes post-dose and then within ± 10 minutes for all subsequent time points. Spirometry equipment and performance of spirometric testing were in accordance with the (ATS / ERS) standards.

Time frame:
5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose
Reported as:
Least squares mean · liters
Serial FEV1 Measurement (i.e. at 5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose) Following Inhalation of a Single Dose of Study Medication to Evaluate the Onset and Duration of the Bronchodilatory Effect
litersMFF10F12MF12DPlacebo
5 minutes1.74 (1.70 to 1.79)1.77 (1.72 to 1.81)1.77 (1.73 to 1.82)1.68 (1.63 to 1.72)
30 minutes1.79 (1.75 to 1.84)1.80 (1.75 to 1.85)1.82 (1.77 to 1.87)1.69 (1.64 to 1.74)
1 hour (N=32, 31, 29, 31)1.81 (1.75 to 1.87)1.80 (1.74 to 1.86)1.86 (1.79 to 1.92)1.72 (1.66 to 1.78)
2 hours1.81 (1.74 to 1.87)1.79 (1.72 to 1.85)1.85 (1.79 to 1.91)1.73 (1.67 to 1.79)
4 hours1.81 (1.73 to 1.88)1.79 (1.71 to 1.87)1.84 (1.76 to 1.92)1.72 (1.64 to 1.80)
8 hours1.76 (1.69 to 1.83)1.75 (1.69 to 1.82)1.79 (1.72 to 1.86)1.70 (1.63 to 1.77)
12 hours1.72 (1.67 to 1.78)1.71 (1.65 to 1.76)1.76 (1.70 to 1.81)1.66 (1.61 to 1.72)
SecondarySerial Forced Vital Capacity (FVC) Measurement (i.e. at 5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose) Following Inhalation of a Single Dose of Study Medication to Evaluate the Onset and Duration of the Bronchodilatory Effect

All efficacy evaluations were based on spirometry assessments of lung function. FVC is the volume (liters) of air that can forcibly be blown out after full inspiration. At Visits 2, 3, 4 and 5, spirometry assessments were performed in the clinic at predose and again at 5 and 30 minutes and 1, 2, 4, 8 and 12 hours post-dose within ± 5 minutes of the scheduled time for the time points up to and including 60 minutes post-dose and then within ± 10 minutes for all subsequent time points. Spirometry equipment and performance of spirometric testing were in accordance with the ATS / ERS standards.

Time frame:
5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose
Reported as:
Least squares mean · liters
Serial Forced Vital Capacity (FVC) Measurement (i.e. at 5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose) Following Inhalation of a Single Dose of Study Medication to Evaluate the Onset and Duration of the Bronchodilatory Effect
litersMFF10F12MF12DPlacebo
5 minutes2.09 (2.04 to 2.14)2.09 (2.05 to 2.14)2.09 (2.04 to 2.13)2.08 (2.03 to 2.13)
30 minutes2.12 (2.07 to 2.17)2.11 (2.06 to 2.16)2.11 (2.06 to 2.16)2.08 (2.03 to 2.13)
1 hour (N=32, 31, 29, 31)2.14 (2.09 to 2.20)2.09 (2.03 to 2.14)2.15 (2.09 to 2.21)2.10 (2.04 to 2.15)
2 hours2.11 (2.05 to 2.17)2.08 (2.02 to 2.14)2.14 (2.08 to 2.20)2.11 (2.05 to 2.17)
4 hours2.12 (2.06 to 2.17)2.08 (2.02 to 2.14)2.12 (2.07 to 2.18)2.11 (2.05 to 2.17)
8 hours2.09 (2.04 to 2.15)2.09 (2.04 to 2.15)2.10 (2.04 to 2.15)2.09 (2.04 to 2.15)
12 hours2.07 (2.01 to 2.13)2.05 (1.99 to 2.11)2.09 (2.03 to 2.15)2.06 (2.00 to 2.12)
SecondarySerial Peak Expiratory Flow Rate (PEF) Measurement (i.e. at 5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose) Following Inhalation of a Single Dose of Study Medication to Evaluate the Onset and Duration of the Bronchodilatory Effect

All efficacy evaluations were based on spirometry assessments of lung function. PEF is the greatest airflow rate achieved during forced exhalation with lungs fully inflated. At Visits 2, 3, 4 and 5, spirometry assessments were performed in the clinic at predose and again at 5 and 30 minutes and 1, 2, 4, 8 and 12 hours post-dose within ± 5 minutes of the scheduled time for the time points up to and including 60 minutes post-dose and then within ± 10 minutes for all subsequent time points. Spirometry equipment and performance of spirometric testing were in accordance with the ATS/ERS standards

Time frame:
5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose
Reported as:
Least squares mean · liters
Serial Peak Expiratory Flow Rate (PEF) Measurement (i.e. at 5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose) Following Inhalation of a Single Dose of Study Medication to Evaluate the Onset and Duration of the Bronchodilatory Effect
litersMFF10F12MF12DPlacebo
5 minutes246.65 (238.31 to 254.99)248.17 (239.72 to 256.63)250.05 (241.48 to 258.62)237.85 (229.40 to 246.30)
30 minutes255.69 (245.56 to 265.81)253.37 (243.14 to 263.59)257.81 (247.48 to 268.14)243.59 (233.36 to 253.82)
1 hour (N=32, 31, 29, 31)261.18 (250.97 to 271.38)257.08 (246.79 to 267.38)262.95 (252.47 to 273.43)248.24 (237.94 to 258.54)
2 hours261.45 (250.74 to 272.17)259.28 (248.45 to 270.10)267.91 (256.98 to 278.84)248.88 (238.05 to 259.70)
4 hours264.68 (253.09 to 276.26)258.92 (247.24 to 270.60)265.20 (253.42 to 276.98)249.07 (237.39 to 260.76)
8 hours257.96 (246.21 to 269.72)255.27 (247.41 to 267.12)262.61 (250.65 to 274.56)248.47 (236.61 to 260.33)
12 hours255.48 (243.94 to 267.02)250.71 (239.06 to 262.37)259.71 (248.05 to 271.37)244.13 (232.59 to 255.66)
SecondaryPlasma Formoterol Concentrations (Pmol/L) Following a Single Dose of Formoterol Fumarate Alone and in Combination With Mometasone Furoate Via the pMDI and Formoterol Fumarate Via the Dry Powder Inhaler (DPI)

Unchanged racemic formoterol in plasma was assayed by LC-MS/MS. The lower limit of quantification (LLOQ) for plasma was 1.45 pmol/L. No non-compartmental PK analysis was performed.

Time frame:
5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose
Reported as:
Mean · pmol/L
Plasma Formoterol Concentrations (Pmol/L) Following a Single Dose of Formoterol Fumarate Alone and in Combination With Mometasone Furoate Via the pMDI and Formoterol Fumarate Via the Dry Powder Inhaler (DPI)
pmol/LMFF10F12MF12D
Pre-Dose (N count MFF=15,F12M=17,F12D=16)0 ± 00 ± 00 ± 0
5-10 minutes (N=16, 17, 17)13.1 ± 12.216.3 ± 18.618.56 ± 9.19
30 minutes - 2 hours (N=16,17,17)27.5 ± 12.224.7 ± 18.723.1 ± 11.08
2 hours - 4 hours (N= 16, 17, 17)22.4 ± 15.117.7 ± 10.517.4 ± 6.44
4 hours - 8 hours (N= 16, 17, 17)12.3 ± 8.0711.0 ± 5.311.3 ± 4.42
8 hours - 12 hours (N= 16, 16, 17)7.74 ± 5.686.66 ± 5.76.83 ± 4.76
SecondaryUrinary Excretion of Formoterol Following a Single Dose of Formoterol Fumarate Alone and in Combination With Mometasone Furoate Via the pMDI and Formoterol Fumarate Via the Dry Powder Inhaler (DPI)

Unchanged racemic formoterol in urine was assayed by LC-MS/MS. The lower limit of quantification (LLOQ) for urine was 0.0174 nmol/L expressed as free base. The amounts of unchanged formoterol excreted in urine from 0 to 3 hours (Ae0-3) and from 0 to 12 hours post-dose (Ae0-12) were calculated from the formoterol concentrations in urine and the urine volumes using non-compartmental methods.

Time frame:
0 to 3 hrs and 0-12 hrs
Reported as:
Least squares mean · nmol
Urinary Excretion of Formoterol Following a Single Dose of Formoterol Fumarate Alone and in Combination With Mometasone Furoate Via the pMDI and Formoterol Fumarate Via the Dry Powder Inhaler (DPI)
nmolMFF10F12MF12D
Ae (0-3) nmol (N=15,17,17)0.31 (0.20 to 0.49)0.52 (0.33 to 0.80)0.42 (0.27 to 0.65)
Ae (0-12) nmol (N=16,17,17)1.14 (0.81 to 1.59)1.50 (1.08 to 2.08)1.33 (0.96 to 1.85)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
F12M—0/31 (0%)0/31 (0%)
F12D—0/31 (0%)0/31 (0%)
MFF10—0/32 (0%)0/32 (0%)
Placebo—0/31 (0%)0/31 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)F12M, PL, F12D, MFFF12D, F12M, MFF, PLMFF, F12D, PL, F12MPL, MFF, F12M, F12DTotal
<=18 years799732
Between 18 and 65 years00000
>=65 years00000
Age Continuous
Age Continuous(years)F12M, PL, F12D, MFFF12D, F12M, MFF, PLMFF, F12D, PL, F12MPL, MFF, F12M, F12DTotal
Mean9.0 ± 1.639.4 ± 1.517.9 ± 1.8310.1 ± 1.219.1 ± 1.72
Sex: Female, Male
Sex: Female, Male(Participants)F12M, PL, F12D, MFFF12D, F12M, MFF, PLMFF, F12D, PL, F12MPL, MFF, F12M, F12DTotal
Female265417
Male534315
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)F12M, PL, F12D, MFFF12D, F12M, MFF, PLMFF, F12D, PL, F12MPL, MFF, F12M, F12DTotal
Hispanic or Latino225211
Not Hispanic or Latino574521
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)F12M, PL, F12D, MFFF12D, F12M, MFF, PLMFF, F12D, PL, F12MPL, MFF, F12M, F12DTotal
American Indian or Alaska Native00011
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American02103
White543416
More than one race00000
Unknown or Not Reported235212
08

Study locations

9 sites
  • Novartis Investigative Site
    Mobile, Alabama 36608, United States
  • Novartis Investigative Site
    Huntington Beach, California 92647, United States
  • Novartis Investigative Site
    Orange, California 92868, United States
  • Novartis Investigative Site
    Hialeah, Florida 33012, United States
  • Novartis Investigative Site
    Pensacola, Florida 32503, United States
  • Novartis Investigative Site
    Oklahoma City, Oklahoma 73112, United States
  • Novartis Investigative Site
    Barranquilla, Colombia
  • Novartis Investigative Site
    Bogota, Colombia
  • Novartis Investigative Site
    Lima, Peru
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2011, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2008
First posted
Sep 4, 2008
Start
Aug 2008
Primary completionActual
Apr 2009
CompletionActual
Apr 2009
Results first posted
Apr 14, 2011
Last update
Jun 7, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00746330
Lead sponsor
Novartis
Collaborators
Schering-Plough
First posted
Sep 4, 2008
Start date
Aug 2008
Primary completion
Apr 2009
Completion
Apr 2009
Results posted
Apr 14, 2011
Last update
Jun 7, 2011
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mometasone Furoate · Formoterol

Start the discussion